A Masked, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ISIS 696844 Administered Subcutaneously to Healthy Volunteers

Trial Profile

A Masked, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ISIS 696844 Administered Subcutaneously to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs ISIS 696844 (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 08 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jan 2017 Planned End Date changed from 25 Oct 2016 to 14 Apr 2017.
    • 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top